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ThrombosisAbstract Sickle cell trait (SCT), the heterozygous state of the sickle hemoglobin beta globin gene
(HbAS) is carried by as many as 100 million individuals including up to 25% of the population in
some regions of the World. Sickle cell trait is the best-characterized genetic polymorphism known to
protect against falciparum malaria. Although SCT was initially considered as a benign condition,
data are accumulating of serious morbidities in SCT individuals including increased incidence of
hematuria, renal papillary necrosis, renal failure and malignancy, thromboembolic disorders, sple-
nic infarction as a high altitude complication, and exercise-related rhabdomyolysis and sudden
death. Despite these associations, the average life span of individuals with sickle cell trait is similar
to that of the general population. Nonetheless, given the large number of people with sickle cell
trait, it is important that physicians be aware of these associations. The aim of this article is to
review publications reporting and discussing morbidities in SCT individuals.
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Sickle hemoglobin (HbS) is a structural variant of normal
adult hemoglobin. Adult hemoglobin (HbA) is made up of
two alpha and two beta globin chains. HbS is the result of a
single point mutation (Gluﬁ Val) on the sixth codon of the
beta globin gene [1]. Homozygotes for hemoglobin S (HbSS)
with two affected beta chains develop sickle cell disease, in
which polymerized hemoglobin causes red blood cells to sickle
and occlude blood vessels. Vaso-occlusion affects many organs
and tissues, and results in high morbidity and mortality [1,2].
Individuals who are heterozygous for HbS are carriers of
the sickle cell trait (SCT). Heterozygous individuals are not
anemic and have normal red cell indices with hemoglobin S
percentages typically near 40% [3]. They generally enjoy nor-
mal life spans without serious health consequences related to
their sickle cell status, but under extreme conditions such as
severe dehydration and high-intensity physical activity, com-
plications such as exertional rhabdomyolysis, splenic infarc-
tion, and papillary necrosis can occur [4].le 1 Adverse events associated with sickle cell trait [6–9].
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plicated hyphemaSickle cell trait occurs in approximately 300 million people
worldwide, with the highest prevalence of approximately 30–
40% in sub-Saharan Africa [1].
In regions of the world where malaria is endemic, SCT con-
fers a survival advantage in childhood malaria; this is thought
to be a major selective pressure for persistence of the HbS
mutation (Glu6Val). [5]
2. Morbid complications in sickle cell trait individuals
Early publications linked SCT to a wide variety of medical
conditions, but many of these studies were small case series
or uncontrolled observational studies [6,7].
Recently the current understanding of the complications
of SCT [8,9] has been revisited, listing them as: (i) ‘‘deﬁnite’’;
(ii) ‘‘probable’’; (iii) ‘‘possible’’; and (iv) ‘‘unlikely’’ when
there is insufﬁcient evidence to suggest an independent asso-
ciation (Table 1 and Fig. 1). However, it should be noted
that the assignment of complications into these categories
was not based on a systematic review of the literature, and
thus the importance of some of the conditions may have been
overrated while others might have been underrated [4].
Despite these associations, the average life span of individu-
als with sickle cell trait is similar to that of the general pop-
ulation. Nonetheless, given the large number of people with
sickle cell trait, it is important that physicians be aware of
these associations.
3. Sickle cell trait and malaria
Sickle cell trait (SCT) is the best-characterized genetic poly-
morphism known to protect against falciparum malaria [8].
In a large follow up study including 800 children and adults
in Kenya the results revealed that SCT had no impact on the
prevalence of asymptomatic parasitemia, it was 50% protec-
tive against mild clinical malaria, 75% protective against hos-
pital admission for malaria, and 90% protective against severe
or complicated malaria [12].
Deﬁnite
Probable
Possible
Unlikely
Complicaons 
of Sickle Cell 
Trait
Renal medullary carcinoma, 
hematuria,renal papillary 
necrosis, hyposthenuria, splenic
infarcon, exeronal
rhabdomyolysis, exercise-related 
sudden death, and protecon 
against severe falciparum malaria
Complicated hyphema, venous
thromboembolism (VTE)
Acute chest syndrome, 
asymptomac bacteriuria in 
pregnancy, proliferave
renopathy , fetal
loss/demise, and low birth weight
Stroke, cholelithiasis, priapism, leg 
ulcers, avascular necrosis of the 
femoral head
Figure 1 Classiﬁcation of complications of sickle cell trait according to strength of reported associations [9–11].
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well known, the mechanism(s) of protection remain unclear
[1]. A number of biochemical and immune-mediated mecha-
nisms have been proposed, and it is likely that multiple com-
plex mechanisms are responsible for the observed protection
[5]. Increased evidence for an immune component of protec-
tion involving the enhancement of both innate and acquired
immunity to the parasite as well as novel mechanisms, such
as enhanced tolerance to disease mediated by HO-1[ Hemeox-
ygenase-1] and reduced parasitic growth due to translocation
of host micro-RNA into the parasite, have recently been
described [13,14].
4. Exercise, exertional rhabdomyolysis and sickle cell trait
SCT is an established risk factor for exercise-related rhabdo-
myolysis and sudden death. Exertional rhabdomyolysis (ER)
can cause death in the general population [4]. The absolute risk
in the general population and, more speciﬁcally, in persons
with SCT, is not known [15].
4.1. Pathophysiology and clinical manifestations of exertional
rhabdomyolysis
ER is an acute clinical syndrome caused by the breakdown of
striated skeletal muscle due to metabolic derangement or phys-
ical injury. Excessive muscular activity results in a state in
which adenosine triphosphate (ATP) production cannot keep
up with the demand, subsequently exhausting cellular energy
supplies leading to a disruption of muscle cell membranes
[16]. Clinical manifestations include severe pain, muscle ten-
derness or swelling, dark urine (myoglobinuria), and serum
creatine kinase (CK) elevations; however, only 50% of patients
have these classic ﬁndings at presentation [4,17].
The more strenuous or prolonged the exercise, the more
damage is incurred in SCT individuals. Factors that increase
the risk of exertional rhabdomyolysis are hypokalemia (oftenresulting from excessive sweating), high altitude, extreme heat
and humidity, exercise-induced asthma, or pre-exertion fatigue
[16]. Noteworthy, rhabdomyolysis cases associated with low-
intensity exercise have also been reported. In these cases the
mechanism remains unknown [4,16].
Rhabdomyolysis (exertional and non-exertional) can have
multisystem consequences or complications such as acute kid-
ney injury, disseminated intravascular coagulopathy, hyperka-
lemia, and cardiac dysrhythmias [16,17].
4.2. Other genetic factors predisposing to exertional
rhabdomyolysis
Apart from SCT, other genetic factors, are likely to inﬂuence
this diverse clinical spectrum of disease and response to
exercise. Genetic mutations causative for McArdle disease,
carnitine palmitoyl transferase deﬁciency 2, myoadenylate
deaminase deﬁciency, and malignant hyperthermia have all
been associated with ER [18]. Polymorphic variations in the
myosin light chain kinase, a-actin 3, creatine kinase-muscle
isoform, angiotensin I-converting enzyme, heat shock protein,
and interleukin-6 genes have also been associated with ER and
increased risk of ER in SCT patients [19].
4.3. Prevention and management of SCT related exertional
rhabdomyolysis
Successful treatment of ER includes early detection, and
immediate measures to prevent renal failure by rapid rehydra-
tion, and correction of hypovolemia and metabolic derange-
ments [16,17].
5. The splenic syndrome in sickle cell trait
Acute splenic syndrome is a rare but well-documented compli-
cation of SCT that can present in the setting of low oxygen ten-
sion that occurs with major changes in altitude, either by
322 A.A.G. Tantawyunpressurized air ﬂight or ground travel such as mountain
climbing [20,21].
5.1. Pathophysiology and clinical manifestations of the splenic
syndrome
The standard scenario of splenic syndrome in patients with
SCT is as follows: patients usually do not know about their
sickle cell genetic status, and most of them have never had
any problems. Shortly after arrival to an area of high altitude,
upper abdominal pain develops that soon localizes itself to the
splenic region in the left hypochondrium. The spleen is usually
enlarged from sequestration of red cells and becomes very ten-
der from vaso-occlusion by sickled red cells, resulting in sple-
nic infarction. The abdomen becomes rigid, with muscle
guarding and, often, rebound tenderness [22,23]. In many of
these patients pleural effusion can develop, especially on the
left side, and a few can even have pulmonary inﬁltration
[24]. Breathing thus becomes shallow, difﬁcult and often pain-
ful, especially at the end of inspiration. Anemia may accom-
pany this presentation, and reticulocyte count and serum
lactate dehydrogenase enzyme levels may increase [24]. How-
ever, there are few reports describing acute splenic infarction
in SCT patients in the absence of hypoxia, possibly related
to infection, dehydration, drugs, and/or muscular exertion
[25,26].
5.2. Management of SCT related splenic syndrome
Once a diagnosis of SCT is established, conservative measures
could obviate surgical management [22]. Splenectomy should
be discouraged in SCT patients presenting with splenic syn-
drome at high altitude. Supportive care should always be the
primary treatment [21,24].
6. Renal complications in sickle cell trait
Renal abnormalities are among the most widely acknowledged
complications of SCT [3]. They include hematuria, papillary
necrosis, hyposthenuria, renal medullary carcinoma and
asymptomatic bacteriuria in pregnancy [9].
6.1. Hematuria in SCT: pathophysiology and management
The renal medulla represents an acidotic environment charac-
terized by low oxygen tension and high interstitial osmolarity.
As blood traverses the slow-moving circuit of the medullary
vasa recta, the hyperosmolar milieu may enhance dehydration
of erythrocytes, allowing sickling in sickle cell disease and
probable vaso-occlusion and medullary microinfarctions [27].
Hematuria is the most common manifestation of SCT, but
its true incidence remains uncertain [28]. Spontaneous sickling
can occur in the renal papilla (normally under low oxygen
pressure) in patients with renal papillary necrosis; therefore,
5% of patients with sickle cell trait can suffer episodes of
hematuria at some point during their lives [27,29]. Bleeding,
is typically painless, presents as microscopic or gross bleeding
and may be associated with renal papillary necrosis [30].
Conservative management of bleeding with bed rest and
aggressive hydration is usually sufﬁcient [28]. In refractorycases, medical intervention with desmopressin, antiﬁbrinolytic
agents such as aminocaproic acid, aprotinin, oral urea or even
invasive intervention with ureteroscopy or angiography, has
been advocated. [31,32].
6.2. Hyposthenuria in sickle cell trait
The majority of SCT patients develop a progressive deteriora-
tion in the capacity for concentrating urine (hyposthenuria)
and even isosthenuria which is directly related with the per-
centage of intra-erythrocyte HbS. Isosthenuria refers to the
excretion of urine in which speciﬁc gravity is neither greater
nor less than that of protein-free plasma, typically 1.008–
1.012. Isosthenuria reﬂects renal tubular damage/failure of
renal medullary function [27,33]. The degree of impairment
of urinary concentration is also variable among subjects with
SCT, and may be related to the percentage of hemoglobin S
[3,8].
Microradiographs of the SCT kidney reveal reduction and
disruption of the vasa recta, the intricate vascular system of
the kidney responsible for generating an osmolar gradient.
Although not as severe as those seen in SCD, these vascular
changes likely lead to the observed impairment of urinary con-
centration in patients with SCT [34].
6.3. The risk of progressive nephropathy in sickle cell trait
Conﬂicting reports exist as to whether sickle cell trait is a risk
factor for the progression of nephropathy and the risk of end
stage renal disease [35–37].
Derebail et al. [36] reported that among 5319 African–
American patients with end-stage renal disease (ESRD) on
hemodialysis, 542 (10.2%) patients had sickle cell trait. Sickle
cell trait was more common in this cohort than the general
African–American population (10.2% vs. 6.5–8.7%, respec-
tively, P< 0.05). They suggested that the higher prevalence
of SCT in the ESRD population raises the possibility that
these hemoglobinopathies contribute to a decline in kidney
function, either alone or in conjunction with other known risk
factors for renal disease.
However, Hicks et al. [37] demonstrated that sickle cell trait
was not associated with diabetic or non-diabetic ESRD in a
large sample of African Americans.
7. Renal medullary carcinoma in sickle cell trait
Renal medullary carcinoma (RMC) is a rare neoplasm of the
kidney that has been ﬁrst described in 1995 [38]. It is almost
exclusive to young patients and associated with sickle cell
hemoglobinopathy, mainly sickle cell trait and hemoglobin
SC disease [39].
7.1. Pathogenesis and clinical presentation of renal medullary
carcinoma
Chronic ischemia has been suggested as a predisposing factor
related to constant regeneration of the distal collecting duct
epithelium giving rise to malignant transformation [3,35],
although reports of RMC in sickle cell anemia are very rare
[40].
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21 years, there are increasing reports of this rare cancer in
childhood age [41]. Most patients present with the triad com-
monly seen in renal carcinoma, that is, gross hematuria, ﬂank
pain, and a palpable abdominal mass. Regional lymphadenop-
athy is common at presentation, as is distant metastatic disease
to liver, lung, pleura, or omentum [42].
7.2. Prognosis of renal medullary carcinoma
The prognosis of RMC is very poor because of the highly
aggressive behavior of this neoplasm and its resistance to con-
ventional chemotherapy [38]. Metastatic disease is almost uni-
versal at the time of presentation, and the malignancy is
minimally responsive to a variety of regimens and/or modali-
ties, including surgery, radiotherapy, chemotherapy, and bio-
logical immune-modulation therapy. [42,43].
8. Thrombo-embolic events and sickle cell trait
Sickle cell disorders, such as Hb SS and Hb SC, are associated
with a hypercoagulable state that may contribute to the vaso-
occlusive episodes observed in these disorders [44]. However,
the epidemiologic evidence to support increased thromboem-
bolic events in SCT has been sparse until recently [8].
8.1. Coagulopathy in sickle cell trait
An interesting study [45] demonstrated that individuals with
SCT had increased coagulation activity, with d-dimers, throm-
bin–antithrombin (TAT) complexes, prothrombin fragment
1.2 being consistent indicators of coagulation activation. How-
ever, the measured markers of coagulation activity in SCT (Hb
AS) were lower than in patients with Hb SC and Hb SS dis-
ease. Their ﬁndings suggested that monocytosis, with the pos-
sible expression of monocyte-derived tissue factor, are
contributing factors to the associated hypercoagulable state.
A recent study [46] demonstrated elevated soluble CD163 as
a marker of monocyte activation in asymptomatic SCT indi-
viduals, although the levels were less than in sickle cell disease
(HbSS) patients, in whom it was signiﬁcantly related to the
severity of sickle cell vasculopathy and vaso-occlusive crises.
Lawrie et al. [47] investigated two sibs, a set of monozygotic
twins with SCT, to establish their procoagulant activity status
as a potential indicator of thrombotic risk. Markers of coagu-
lation activation were markedly elevated in one patient but
within the normal in the other patient, although ﬂow cytomet-
ric analysis for RBC-derived microparticles showed elevated
levels in both patients on two occasions. They suggested that
there may be two levels of hypercoagulability in SCT. Mea-
surement of such differences would allow for separation of
individuals at high or low-risk for serious complications.
8.2. Epidemiological studies of thrombo-embolic events in SCT
Recent published data [33] including analysis of a total of
13,964 adult African Americans registered in the Kaiser
Permanente Northern California (KPNC) health system
(Oakland, CA, USA), including 2642 with sickle cell trait,
11,183 with normal hemoglobin (Hb) and 139 with sickle celldisease revealed that the adjusted relative risk of pulmonary
embolism in sickle cell trait patients compared to patients with
normal Hb was 1.37 [95% conﬁdence interval (CI) 1.07–1.75].
Austin 2007 [48] conducted a case-control study of venous
thromboembolism that included 515 hospitalized black
patients and 555 black controls obtained from medical clin-
ics. They found that the risk of venous thromboembolism
is increased approximately 2-fold among blacks with sickle
cell trait compared with those with the normal genotype
(odds ratio = 1.8 with 95% conﬁdence interval, 1.2–2.9).
The odds ratio for pulmonary embolism and sickle cell trait
was higher, 3.9 (2.2–6.9). They concluded that sickle cell trait
is a risk factor for venous thromboembolism (VTE) and that
the proportion of venous thromboembolism among blacks
attributable to the mutation is approximately 7%. Later on
[49] the authors reported that hormonal contraceptive use
increases venous thromboembolism risk among women with
sickle cell trait.
8.3. Thromboembolic events and pregnancy in sickle cell trait
A recent retrospective cohort study [50] included 22,140 black
American women with hemoglobin (Hb) AA status, and 2037
women with SCT studied during pregnancy or the puerperium.
They reported that the relative risk (RR) of VTE for the asso-
ciation with SCT status = 1.6; 95% conﬁdence interval (CI)
0.5 to 5.5 compared to RR= 32.2, 95% CI 9.7 to 107 in the
presence of Hb SS or SC disease. They concluded that sickle
cell trait may be associated with a modest increase in VTE in
the setting of pregnancy
However, in a large recent study, Pintova et al. [51] studied
12,429 women, 679 non-Hispanic SCT black women, 5465
non-Hispanic Hemoglobin AA black women and 1162 non-
Hispanic HbAA white women were included in the analysis.
Proportions with VTE were similar for black SCT and black
HbAA groups. There was no increase in the incidence of pul-
monary embolism in the SCT group. They could not detect a
meaningful difference in peripartum VTE incidence between
women with and without sickle cell trait.
9. Perinatal and maternal outcomes in women with sickle cell
trait
Although early studies [6,9] reported increased fetal loss and
preeclampsia in women with SCT. In a recent large study, peri-
natal mortality and preeclampsia were not increased in carriers
of sickle cell trait, as well as the risks of stillbirths and preg-
nancy-associated hypertension were not increased [10]. Simi-
larly, a systematic search study in the Cochrane Library,
Medline, EMBASE and CINAHL databases reported no sig-
niﬁcant effect of SCT for low birth weight, growth retardation,
or hypertension; only the risks of anemia and bacteriuria were
increased [11].
10. Sickle cell trait and the eyes
Sickle trait is traditionally considered a benign condition by
ophthalmologists. Patients with sickle trait are at risk of reti-
nopathy if coincident ocular trauma or systemic disease is pres-
ent [52,53].
324 A.A.G. Tantawy10.1. Pathogenesis of complicated hyphemas in sickle cell trait
Sickle cell trait is a signiﬁcant risk factor for complicated trau-
matic hyphemas following blunt trauma, because of increased
risk of secondary hemorrhage, anterior and posterior synech-
iae, increased intraocular pressure, and glaucomatous optic
atrophy, and permanent visual impairment [54,55].
The possible explanation is that there is more sickling of
erythrocytes in the aqueous humor of the eye in vivo and
in vitro than in venous blood. This difference is dependent
on the concentration of HbS in the erythrocytes as well as
the anterior chamber environment. In SCT, there is delay in
the resolution of anterior chamber hyphema due to sickling
of erythrocytes and subsequent obstruction within the trabec-
ular meshwork and Schlemm’s canal leading to rise in intraoc-
ular pressure and the production of secondary glaucoma [6].
11. Other potential morbidities in sickle cell trait
11.1. Priapism
Priapism reported in SCT is rare, the recently reported cases in
literature were associated with another predisposing factor
mostly drugs or co-morbid conditions like surgery or thrombo-
philia [56–59].
11.2. Cerebral stroke
The increased risk of cerebral stroke in sickle cell trait is a sub-
ject of debate [60,61]. In a large retrospective study, Bucknor
[33] reported no increased risk of ischemic stroke in sickle cell
trait patients compared to patients with normal Hb. Most
reported cases in the literature are adults, very few childhood
cases, co-morbidities could play important additional predis-
posing factors [62,63].
11.3. Acute chest syndrome
There are sporadic reports in the literature of acute chest syn-
drome in SCT individuals, mostly precipitated by exposure to
heat, dehydration or infection. In these situations high fatality
is related to previously undiagnosed SCT condition delaying
proper management mainly with hydration, metabolic correc-
tions and in severe conditions, exchange transfusion is life sav-
ing [64,65].
11.4. Osteonecrosis
Osteonecrosis of the femoral head and leg ulcers caused by
sickle cell trait are very rarely reported and only in old refer-
ences [66–69].
12. Conclusions
Although the average life span of individuals with sickle cell
trait is similar to that of the general population, the condition
may be associated with serious life threatening morbidity.
Awareness of the individual and the treating physician of the
sickle cell carrier state is important, to take preventive mea-
sures and to intervene properly and early in critical situations.Early accurate diagnosis and proper management will reduce
the risk of long term morbid sequelae and mortality. Further
research studies are needed to identify the potential genetic
modiﬁers of phenotypic expression of SCT and the impact of
co-morbid conditions such as asthma or diabetes mellitus on
the clinical outcomes in individuals with SCT, as well as pos-
sible genetic or non genetic risk factors that predispose SCT
individuals to thrombotic events. Other potential complica-
tions and aspects of SCT morbidity should be further investi-
gated, including renal and coagulation complications and the
importance of access to genetic counseling.Conﬂict of interest
The author has nothing to declare.
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